Intelligence · Clinical Development
Pipeline search results
Programs matching “ruxolitinib” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 13 pipeline programs matching "ruxolitinib" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
MaaT013
Lacuna Pharma Pty Ltd
Treatment of acute graft-versus host disease (aGvHD) to the gastrointestinal (GI) tract of patients who are resistant or intolerant to ruxolitinib.
1 trial -
Ruxolitinib
Novartis Pharmaceuticals
Polycythemia Vera
1 trial -
2G-MSC-GVHD
The George Institute
Patients who have developed acute GVHD refractory to corticosteroids and ruxolitinib or that are not eligible to receive ruxolitinib
1 trial -
Azacitidine (AZA) with Ruxolitinib
The First People's Hospital of Lianyungang
MDS/MPN
1 trial -
Prednisone + Jakavi(ruxolitinib)
Yung NA
GVHD - Graft-Versus-Host Disease
1 trial -
Rituximab Paclitaxel Ruxolitinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Refractory Diffuse Large B-cell Lymphoma
1 trial -
Ruxolitinib
The First People's Hospital of Lianyungang
Bronchiolitis Obliterans Syndrome
1 trial -
Ruxolitinib
RIGEL PHARMACEUTICALS INC
Coronavirus
1 trial -
Ruxolitinib
ACTUATE THERAPEUTICS, INC.
Myelofibrosis
1 trial -
Ruxolitinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
aGVHD
1 trial -
Ruxolitinib 5 MG BID Oral Tablet
Xiyuan Hospital of China Academy of Chinese Medical Sciences
The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA
1 trial -
Ruxolitinib
The First People's Hospital of Lianyungang
Safety and Efficacy
2 trials -
Ruxolitinib+Calcineurin inhibitor+Methotrexate
The First People's Hospital of Lianyungang
Graft Versus Host Disease
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.